As FDA Suicidality Reviews Become More Common, Firms Move Into C-CASA
Executive Summary
FDA's review of anticonvulsant drugs for suicidality risks suggests that firms should reevaluate their clinical development strategies to anticipate a growing need for such data
You may also be interested in...
Suicidality Screening For All New Drugs Still On The Table After Draft Guidance
FDA lists eight drug classes where it will recommend prospective assessment of suicidality risk, but it invites comments on broadening the criteria.
Antiepileptics Show Risk Of Suicidality, May Cause Labeling Convulsions
FDA findings of an increased risk of suicidality in patients given antiepileptic drugs will likely lead to broad class labeling changes, according to a MedWatch alert issued Jan. 31
Antiepileptics Show Risk Of Suicidality, May Cause Labeling Convulsions
FDA findings of an increased risk of suicidality in patients given antiepileptic drugs will likely lead to broad class labeling changes, according to a MedWatch alert issued Jan. 31